What is the regulatory outlook for emerging non-pharmacological FDA-approved devices targeted at treating primary insomnia without medication?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
What is the regulatory outlook for emerging non-pharmacological FDA-approved devices targeted at treating primary insomnia without medication?
4 real searches · 1 real-search pass
FDA regulatory status nonpharmacological devices primary insomnia insomnia device 510(k) De Novo 2026 Somryst CESGoogle ↗
OBSERVEDReason
FDA guidance digital health devices insomnia CBT-I Somryst FDA De Novo authorizationGoogle ↗
OBSERVEDOther / navigational
FDA cleared device insomnia cranial electrotherapy stimulation insomnia 510(k) Alpha-Stim Fisher WallaceGoogle ↗
OBSERVEDOther / navigational
FDA medical device clinical trials insomnia nonpharmacological neuromodulation device FDA regulatory pathway 2025 2026Google ↗
OBSERVEDReason
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
ChatGPT real searches (4)
Classes come from the query-classifier (a local Laya model). 4 of 4 calls are low-confidence (under 50%) — hover a query in the table to see its confidence.
Searches and sources
ChatGPT4 real searches · gpt-6
FDA regulatory status nonpharmacological devices primary insomnia insomnia device 510(k) De Novo 2026 Somryst CES Google ↗
FDA guidance digital health devices insomnia CBT-I Somryst FDA De Novo authorization Google ↗
FDA cleared device insomnia cranial electrotherapy stimulation insomnia 510(k) Alpha-Stim Fisher Wallace Google ↗
FDA medical device clinical trials insomnia nonpharmacological neuromodulation device FDA regulatory pathway 2025 2026 Google ↗
- accessdata.fda.gov · accessdata.fda.gov
- NEUROVALENS · accessdata.fda.gov
- Product Classification · accessdata.fda.gov
- Product Classification · accessdata.fda.gov
- 84 FR 70003 - Neurological Devices; Reclassification of Cranial Electrotherapy Stimulator Devices Intended To Treat Anxiety and/or Insomnia; Effective Date of Requirement for Premarket Approval for Cranial Electrotherapy Stimulator Devices Intended To Treat Depression - Content Details · govinfo.gov
- Genesis Sleep (K252951) — FDA 510(k) · fda.innolitics.com
- DHAC November 6, 2025 Executive Summary · fda.gov
- Regulatory Overview for Neurological Devices · fda.gov
- sec.gov · sec.gov
- sec.gov · sec.gov
- Quality Management System Regulation (QMSR) · fda.gov
- Quality Management System Regulation – Frequently Asked Questions · fda.gov
Queries
4 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
FDA regulatory status nonpharmacological devices primary insomnia insomnia device 510(k) De Novo 2026 Somryst CES OBSERVED | Google ↗ AI Mode ↗ | — | Reason | — | — | 1x of 1 | |
FDA guidance digital health devices insomnia CBT-I Somryst FDA De Novo authorization OBSERVED | Google ↗ AI Mode ↗ | — | Other / navigational | — | — | 1x of 1 | |
FDA cleared device insomnia cranial electrotherapy stimulation insomnia 510(k) Alpha-Stim Fisher Wallace OBSERVED | Google ↗ AI Mode ↗ | — | Other / navigational | — | — | 1x of 1 | |
FDA medical device clinical trials insomnia nonpharmacological neuromodulation device FDA regulatory pathway 2025 2026 OBSERVED | Google ↗ AI Mode ↗ | — | Reason | — | — | 1x of 1 |